Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Pacific Edge has expanded the international market for two new molecular tests that provide better detection and management of urothelial cancer. To download the full article, please sign in.
MD Anderson Cancer Center is one of the largest and most respected centers of its kind in the world, with a wealth of resources and expertise to offer biopharmaceutical companies aiming to catapult next-generation cancer therapies into the clinic.
The Institut Pasteur is harnessing a powerful combination of in-house research strengths to explore the relationship between the microbiome and the brain. The institute is looking for partners eager to take advantage of this unique opportunity to learn more about the gut–brain axis.
Using a unique combination of computational chemistry, pharmacology and cheminformatics methods, Re-Pharm is successfully reprofiling marketed compounds as early stage candidates ready for partnering.
Three collaborative platforms—a Center for Innovation (COI), a tripartite industry-academia group (DUCR, TLO and UTEC) and the Translational Research Initiative (TRI)—showcase the University of Tokyo’s commitment to the development and commercialization of new healthcare technologies.
A leader in CNS specialty medicine sales in the United States and in the top five globally, Teva Pharmaceuticals is actively looking to expand its CNS portfolio further.
New company Astrocyte Pharmaceuticals is pioneering a novel approach to healing a damaged brain that involves activating energy supplies in astrocytes, the abundant star-shaped brain cells with a central role in repairing CNS injury.
Three collaborative platforms—a Center for Innovation (COI), a tripartite industry-academia group (DUCR, TLO and UTEC) and the Translational Research Initiative (TRI)—showcase the University of Tokyo’s commitment to the development and commercialization of new healthcare technologies. To download the full article, please sign in.
Crescendo Biologics is poised to significantly impact the world of antibody therapeutics with the enormous potential of its Humabody technology and its product-discovery and engineering capabilities.
Sanford Burnham Prebys Medical Discovery Institute is an independent, nonprofit biomedical research institute that combines deep expertise in fundamental and translational science to discover innovative medicines and diagnostics.
With its unique LentiVector platform and expanding state-of-the-art manufacturing facilities, Oxford BioMedica has established itself as the partner of choice for companies developing advanced therapy medicinal products.
Cellect Biomed has developed a stem cell selection process it hopes will optimize clinical and research applications of stem cells and provide a boon to the stem cell industry. The company’s ultimate goal is to make stem cell transplantation a safer and more effective medical procedure.
Regenerative medicine company International Stem Cell Corporation (ISCO) leads the way in developing new treatments for Parkinson’s disease and other clinical conditions using a unique stem cell approach.
